GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd shares are currently trading at Rs 2,421 which is at an increase of 20 percent.

ICICI Securities raised its estimates on GSK Pharma for the company’s FY25–26E earnings per share, to approximately 5 to 6 percent. This was mainly due to better margin outlook. Therefore, it upgraded its rating of the shares to ‘Add’ with lower target price of Rs 2,250 based on 38x FY26 estimates of earnings per share.

Meanwhile, Motilal Oswal also increased its earnings estimates for the company by 2 percent/5 percent/7 percent for FY25/FY26/FY27 to factor in a) differentiated launches in cancer therapy, b) scale-up of vaccine business, c) enhanced efforts to boost vaccine prospects. The brokerage valued GSK Pharma at a target price of Rs 2,170.

For the quarter ended December, of the current fiscal year 2025, the company’s revenue from operations grew by 17.9 percent YoY to Rs 9.5 billion while its gross margin (GM) contracted by 150bp YoY, to reach 62.2 percent. The decline was a result of a change in the product mix.

Related Posts

Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

New Delhi: Union Commerce and Industry Minister Piyush Goyal has discussed strategies to boost competitiveness and strengthen research and development activities with the business representatives of the pharmaceutical industry. “Had…

Senores Pharma to Buy Two Teva ANDAs

Mumbai, August 14, 2025 — Senores Pharmaceuticals will acquire two abbreviated new drug applications (ANDAs) from Teva Pharmaceuticals USA. The deal is Senores’ third US move in six months, underscoring…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

Senores Pharma to Buy Two Teva ANDAs

Senores Pharma to Buy Two Teva ANDAs

Lab-grown rabies antibodies show promise as cheaper, safer alternative

Lab-grown rabies antibodies show promise as cheaper, safer alternative

Lilly launches Mounjaro KwikPen in India

Lilly launches Mounjaro KwikPen in India